source
- Lilly pens deal with Gateway Labs alumni Amplitude for RNA vaccine platform for infectious diseaseEli Lilly has turned to one of its Gateway Labs residents to help the Big Pharma develop trans-amplifying RNA (taRNA) vaccines for infectious diseases.Fierce Biotech · 7h ago↗ source
- Regeneron halts Phase 1/2a uveitis trial of anti-CD3 antibody after safety eventRegeneron announced it is voluntarily ending the Phase 1/2a TITAN study of its anti‑CD3 monoclonal antibody, REGN7041, which was being evaluated for non‑infectious posterior uveitis. The decision…